Immune-Onc Therapeutics Names Gurney, Klencke to its Board of Directors
10 November 2022 - - US-based clinical-stage cancer immunotherapy company Immune-Onc Therapeutics, Inc has appointed Austin L. Gurney, Ph.D. and Barbara J. Klencke, M.D. to the company's board of directors, the company said.

Austin Gurney, Ph.D. is a biotech industry veteran with over two decades of experience in the discovery and development of novel therapeutics.

He was chief scientific officer, senior vice president of research at OncoMed Pharmaceuticals where he held various management roles of increasing responsibility between 2004 and 2017. During this time, he and his teams discovered and developed five first-in-class therapeutic agents.

Prior to OncoMed, Austin worked at Genentech where his research led to the discovery of several growth factors and cytokines.

He has authored or co-authored more than 60 published scientific papers and is listed as an inventor on over 600 patents related to therapeutic applications in immunology and cancer.

Austin received his Ph.D. in biology from Case Western Reserve University.

Barbara J. Klencke, M.D. is a drug developer and research and development expert, having made significant contributions to the oncology community with the development and approval of several first-in-class therapies.

Since 2015, she has served as the chief medical officer of Sierra Oncology Inc., a publicly traded clinical-stage biopharmaceutical company recently acquired by GSK in 2022.

From 2011 to 2015, Barbara served as senior vice president of global development at Onyx Pharmaceuticals, acquired by Amgen Inc. in 2013.

She also led a variety of both early- and late-stage oncology programs while at Genentech, Inc. from 2003 to 2011.

Barbara received her M.D. from the University of California, Davis (UC Davis) and completed her internal medicine residency and hematology/oncology fellowship at the University of California, San Francisco and remained at UCSF as an assistant professor of medicine in oncology focusing on clinical research from 1995 2002.

Immune-Onc Therapeutics Inc is a private, clinical-stage cancer immunotherapy company dedicated to the discovery and development of novel myeloid checkpoint inhibitors for cancer patients.

The company aims to translate unique scientific insights in myeloid cell biology and immune inhibitory receptors to discover and develop first-in-class biotherapeutics that inhibit immune suppression in the tumor microenvironment.

Immune-Onc has a differentiated pipeline with a current focus on targeting the Leukocyte Immunoglobulin-Like Receptor subfamily B (LILRB) of myeloid checkpoints.

Immune-Onc's focused platform approach has led to the development of several promising therapeutics across various stages of development.

Those include IO-108, an antagonist antibody targeting LILRB2 (also known as ILT4), in Phase 1 clinical development for solid tumors and IO-202, a first-in-class antagonist antibody targeting LILRB4 (also known as ILT3), in Phase 1 clinical development for the treatment of acute myeloid leukemia, chronic myelomonocytic leukemia, and solid tumors.

Additional assets in Immune-Onc's pipeline include IO-106 (first-in-class antagonist antibody targeting LAIR1), IO-312 (bi-specific antibody targeting LILRB4), and multiple undisclosed programs for solid tumors and hematologic malignancies.

Immune-Onc has established agreements with leading biopharmaceutical companies, including BeiGene and Regeneron, to support its global product development plans for IO-108 and IO-202.

It has received research grants from the National Cancer Institute of the National Institutes of Health and the California Institute for Regenerative Medicine and investment from The Leukemia and Lymphoma Society Therapy Acceleration Program (LLS TAP).